Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
暂无分享,去创建一个
N. Girard | M. Ladanyi | V. Rusch | C. Azzoli | W. Travis | W. Pao | C. Deshpande
[1] J. Benfield,et al. Clonal Origin of Multiple Lung Cancers: K‐ras and p53 Mutations Determined by Nonradioisotopic Single‐strand Conformation Polymorphism Analysis , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[2] T. Nagayasu,et al. Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers. , 2007, Clinical lung cancer.
[3] Julio Astudillo,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.
[4] C. Mountain,et al. Revisions in the International System for Staging Lung Cancer. , 1997, Chest.
[5] M. Ladanyi,et al. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. , 2005, The Journal of molecular diagnostics : JMD.
[6] V. Seshan,et al. Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] Yih-Leong Chang,et al. Clonality and Prognostic Implications of p53 and Epidermal Growth Factor Receptor Somatic Aberrations in Multiple Primary Lung Cancers , 2007, Clinical Cancer Research.
[8] R. Munden,et al. Management of small (3-5-mm) pulmonary nodules at chest CT: global survey of thoracic radiologists. , 2008, Radiology.
[9] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[10] G. Giaccone,et al. Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Synchronous multiple primary lung cancers with different response to gefitinib. , 2006, Lung cancer.
[12] G. Snow,et al. Second primary tumors and field cancerization in oral and oropharyngeal cancer: Molecular techniques provide new insights and definitions , 2002 .
[13] W. Gerald,et al. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.
[14] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[15] E. Mark,et al. Carcinogen exposure, p53 alteration, and K‐ras mutation in synchronous multiple primary lung carcinoma , 1999, Cancer.